AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Vor Biopharma Inc (NASDAQ:VOR)
1.1106 USD
+0.221 24.787%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.89 |
|---|---|
| Change | +0.221 24.787% |
| 52 W H/L (in USD) | 5.700/1.490 |
| EBITDA (in USD) | -124.342M |
| PE Ratio | -- |
| Volume | 39500489 |
| Diluted Eps TTM | -1.77 |
| Total Assets (in USD) | 209.828M |
|---|---|
| Total Liabilities (in USD) | 59.104M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 31.36M |
| Market Cap (in USD) | 106.144 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Vor Biopharma Inc
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees: 168
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Robert Ang M.B.A., M.D., MBBS | Pres, CEO & Director | 1975 |
| 2. | Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer | 1973 |
| 3. | Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board | 1971 |
| 4. | Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer | 1977 |
| 5. | Ms. Tania Philipp | Chief People Officer | 1972 |
| 6. | Dr. Robert G. Pietrusko Pharm.D., Pharm. D. | Chief Regulatory & Quality Officer | 1948 |
| 7. | Mr. John C. King M.B.A. | Chief Commercial Officer | 1976 |
| 8. | Dr. Veit Schmelmer Ph.D. | Sr. VP of Program & Alliance Management | NA |
| 9. | Dr. Eyal C. Attar M.D. | Chief Medical Officer | 1971 |
| 10. | Dr. Robert Ang M.B.A., M.D., MBBS | President, CEO & Director | 1975 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.070 1.581% | 68.76 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.420 3.640% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.740 0.618% | 442.99 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.606 0.500% | 521.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -92.094M | -68.899M | -43.337M | -10.839M | -4.152M |
| Minority Interest | - | - | - | - | - |
| Net Income | -90.77M | -68.78M | -43.337M | -11.447M | -4.152M |
| Selling General Administrative | 28.868M | 21.489M | 11.748M | 4.217M | 0.427M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 2.525M | 1.434M | 0.605M | 0.091M | 0.02M |
| Ebit | -93.418M | -69.018M | -43.366M | -10.417M | -2.86M |
| Ebitda | -90.893M | -67.584M | -42.732M | -10.172M | -2.84M |
| Depreciation And Amortization | 2.525M | 1.434M | 0.634M | 0.245M | 0.02M |
| Operating Income | -93.418M | -69.018M | -43.366M | -10.417M | -2.86M |
| Other Operating Expenses | 93.418M | 69.018M | 43.366M | 10.417M | 2.86M |
| Interest Expense | 1.324M | 1.553M | 0M | 0.608M | 1.003M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 1.324M | 0.119M | 0.029M | 0.154M | 0M |
| Net Interest Income | 1.324M | 0.119M | 0.029M | -0.454M | -1.003M |
| Income Tax Expense | -1.324M | -0.119M | -0.029M | 0.608M | -0.289M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 93.418M | 69.018M | 43.366M | 10.417M | 2.86M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 1.324M | 0.119M | 0.029M | -0.422M | -0.289M |
| Net Income From Continuing Ops | -92.094M | -68.899M | -43.337M | -10.839M | -4.152M |
| Net Income Applicable To Common Shares | -92.094M | -70.127M | -49.262M | -12.612M | -4.152M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 209.828M | 299.366M | 242.59M | 75.908M | 9.826M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.628M | 2.337M | 2.094M | 0.1M | 0.205M |
| Total Liab | 59.104M | 48.759M | 26.327M | 27.637M | 2.186M |
| Total Stockholder Equity | 150.724M | 250.607M | 216.263M | 48.271M | 7.64M |
| Other Current Liab | 10.927M | 8.075M | 0.434M | 0.723M | 1.493M |
| Common Stock | 0.007M | 0.007M | 0.004M | 0.001M | - |
| Capital Stock | 0.007M | 0.007M | 0.004M | 107.337M | 25.069M |
| Retained Earnings | -340.08M | -222.217M | -130.123M | -61.224M | -17.887M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 5.338M | 5.668M | 4.957M | 1.559M |
| Cash | 31.36M | 57.706M | 119.801M | 48.539M | 6.466M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 15.572M | 13.119M | 10.153M | 10.207M | 2.186M |
| Current Deferred Revenue | - | - | 6.335M | 6.26M | - |
| Net Debt | 4.3M | -18.794M | -101.788M | -30.246M | -6.466M |
| Short Term Debt | 3.83M | 3.272M | 1.839M | 0.863M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 35.66M | 38.912M | 18.013M | 18.293M | - |
| Other Stockholder Equity | 490.874M | 473.587M | 346.382M | 2.158M | 0.458M |
| Property Plant Equipment | - | 12.634M | 6.853M | 21.845M | 0.728M |
| Total Current Assets | 140.803M | 236.95M | 214.399M | 49.106M | 7.539M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 105.815M | 172.539M | 87.668M | - | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 0.815M | 1.772M | 1.545M | 2.361M | 0.693M |
| Accumulated Other Comprehensive Income | -0.077M | -0.77M | -242.59M | - | -0.121M |
| Non Currrent Assets Other | 4.812M | 5.338M | 5.668M | 4.957M | 1.559M |
| Non Current Assets Total | 69.025M | 62.416M | 28.191M | 26.802M | 2.287M |
| Capital Lease Obligations | 35.66M | 38.912M | 18.013M | 18.293M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -85.629M | -87.757M | -4.161M | -0.748M | -87.757M |
| Total Cashflows From Investing Activities | -94.091M | -91.651M | -4.161M | -0.748M | -0.748M |
| Total Cash From Financing Activities | 117.14M | 232.911M | 82.526M | 17.699M | 2.464M |
| Net Income | -92.094M | -68.899M | -43.337M | -10.839M | -4.152M |
| Change In Cash | -62.095M | 72.116M | 42.073M | 7.096M | -0.197M |
| Begin Period Cash Flow | 122.214M | 50.098M | 8.025M | 0.929M | 1.126M |
| End Period Cash Flow | 60.119M | 122.214M | 50.098M | 8.025M | 0.929M |
| Total Cash From Operating Activities | -85.144M | -69.144M | -36.292M | -9.855M | -2.661M |
| Depreciation | 2.525M | 1.434M | 0.605M | 0.091M | 0.02M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 4.451M | 187.536M | - | - | - |
| Other Cashflows From Financing Activities | 1.165M | 43.713M | 0.259M | -0.748M | 2.464M |
| Capital Expenditures | 8.462M | 3.894M | 4.161M | 0.748M | 0.748M |
| Change In Working Capital | -12.693M | -9.185M | 4.316M | 0.145M | 0.063M |
| Other Non Cash Items | 6.423M | 3.191M | 0.782M | 0.608M | 1.003M |
| Free Cash Flow | -93.606M | -73.038M | -40.453M | -10.603M | -2.661M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 2111359 |
| 2. | Fidelity Growth Company Fund | 1 year ago | 1457945 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1385613 |
| 4. | Fidelity Select Biotechnology | 1 year ago | 1114702 |
| 5. | iShares Russell 2000 ETF | 1 year ago | 776405 |
| 6. | Fidelity VIP Growth Initial | 1 year ago | 618395 |
| 7. | Fidelity Capital Appreciation | 1 year ago | 610405 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 519630 |
| 9. | Fidelity Growth Company K6 | 1 year ago | 519259 |
| 10. | Fidelity Advisor Equity Growth I | 1 year ago | 474267 |
| 11. | iShares Russell 2000 Value ETF | 1 year ago | 383065 |
| 12. | Fidelity Small Cap Index | 1 year ago | 337057 |
| 13. | Fidelity Series Growth Company | 1 year ago | 286032 |
| 14. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 256600 |
| 15. | Fidelity Growth Discovery | 1 year ago | 246291 |
| 16. | Fidelity Extended Market Index | 1 year ago | 211029 |
| 17. | A4Investments SICAV SIF ACCI IlanaA2EURH | 1 year ago | 200000 |
| 18. | Vanguard Russell 2000 ETF | 1 year ago | 140225 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 138900 |
| 20. | Range Cancer Therapeutics ETF | 1 year ago | 128388 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 2251411 |
| 2. | Vanguard Group Inc | 1 year ago | 1812899 |
| 3. | Woodline Partners LP | 1 year ago | 1111123 |
| 4. | Johnson & Johnson | 1 year ago | 1074658 |
| 5. | Geode Capital Management, LLC | 1 year ago | 794063 |
| 6. | Sarissa Capital Management LP | 1 year ago | 618000 |
| 7. | State Street Corporation | 1 year ago | 608007 |
| 8. | Northern Trust Corp | 1 year ago | 397221 |
| 9. | Mccormack Advisors International | 1 year ago | 357151 |
| 10. | Ensign Peak Advisors Inc | 1 year ago | 346087 |
| 11. | Morgan Stanley - Brokerage Accounts | 1 year ago | 172061 |
| 12. | Millennium Management LLC | 1 year ago | 158392 |
| 13. | Exchange Traded Concepts, LLC | 1 year ago | 154436 |
| 14. | Bridgeway Capital Management, LLC | 1 year ago | 132700 |
| 15. | RA Capital Management, LLC | 1 year ago | 22748880 |
| 16. | FMR Inc | 1 year ago | 7618948 |
| 17. | Paradigm Biocapital Advisors LP | 1 year ago | 6457293 |
| 18. | 5AM Venture Management, LLC | 1 year ago | 6361723 |
| 19. | LAURION CAPITAL MANAGEMENT LP | 1 year ago | 3182889 |
| 20. | Artal Group S A | 1 year ago | 2347424 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...